[2026 Consumer Recommendation No.1 Brand] NKCL Bio

NKCL Bio Group (NKCL Bio) has won the Grand Prize in the Advanced Regenerative Medicine category at the 2026 Consumer Recommendation No.1 Brand Awards hosted by the Chosun Ilbo.

Recently, the advanced regenerative medicine market has been shifting beyond the development of cell therapy technologies toward actual clinical application and the establishment of operational systems. 

NKCL Bio is drawing attention for supporting not only technology supply but also process management for medical institutions and the establishment of GMP (Good Manufacturing Practice)-based manufacturing systems. 

The company is strengthening field-oriented execution structures centered on clinical-manufacturing integration systems, thereby enhancing its responsiveness to market demands.

In particular, its collaboration with Kosin University Gospel Hospital is being evaluated as a representative example of the direction pursued by NKCL. 

The two organizations are jointly conducting clinical research on NK cell combination therapy targeting hepatocellular carcinoma, increasing the potential for realizing precision medicine based on advanced regenerative medicine. 

Together with Han Family Hospital under the Jeonil Medical Foundation, NKCL is also promoting the establishment of an integrated clinical-manufacturing platform for advanced regenerative medicine. 

Through this, the company plans to continuously expand collaboration models and clinical-manufacturing integration system directions tailored to each hospital’s environment and operational objectives.

An official from NKCL Bio stated, “We plan to continue focusing on building operational structures that can be practically applied in real clinical settings while working together with medical institutions.”

https://www.chosun.com/special/special_section/2026/05/28/MLSU6KDDSBHX3GNOBISX3J5KB4/